$0.35
-0.04 (-9.77%)
Open$0.39
Previous Close$0.39
Day High$0.41
Day Low$0.35
52W High$1.60
52W Low$0.34
Volume—
Avg Volume68.4K
Market Cap13.26M
P/E Ratio—
EPS$-0.23
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+9,223.1% upside
Current
$0.35
$0.35
Target
$32.64
$32.64
$20.70
$32.64 avg
$34.69
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 3.70M | 3.63M | 4.58M |
| Net Income | -8,808,201 | -7,787,976 | -1,151,647 |
| Profit Margin | -238.3% | -226.4% | -25.2% |
| EBITDA | -8,605,265 | -8,031,242 | -1,556,423 |
| Free Cash Flow | — | — | -1,101,967 |
| Rev Growth | +1.8% | +1.8% | +24.2% |
| Debt/Equity | 4.08 | 4.08 | 0.58 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $294.45 | -0.18% | 49.3 | 509.50B |
| AMGN | Amgen Inc | $467.06 | -0.22% | 26.5 | 248.84B |
| GILD | Gilead Sciences Inc | $167.95 | -1.05% | — | 208.28B |
| VRTX | Vertex Pharmaceuticals Inc | $542.62 | -0.81% | 34.5 | 137.12B |
| REGN | Regeneron Pharmaceuticals | $951.19 | -0.86% | 19.4 | 93.39B |
| ALNY | Alnylam Pharmaceuticals Inc | $156.65 | -2.00% | 7.7 | 20.98B |